23/10/2014 - Press release
Researchers at the Hospital del Mar have discovered one of the key mechanisms in the development and progression of mycosis fungoide, a type of cancer originating in the lymphoid cells that develops initially on the skin. The study, published in the Journal of Investigative Dermatology, was co-led by Fernando Gallardo, a dermatologist at the Hospital del Mar and a researcher in the translational research group on haematopoietic malignancies at the Hospital del Mar Medical Research Institute (IMIM); Luis Espinosa and Anna Bigas from the IMIM Cancer Stem Cells Laboratory; Juan Sandoval, researcher at the La Fe Research Institute (IISlaFe); and Ángel Diaz, researcher at the Bellvitge Biomedical Research Institute (IDIBELL). The project was conducted with a series of skin samples from patients with mycosis fungoide in tumour phase and led to the identification of the miR-200C molecule as a possible therapeutic target for designing future treatments for this disease.
Més informació "A new therapeutic target identified for the most widespread cutaneous lymphoma"
14/10/2015 - Press release
An international study led by researchers from IMIM (Hospital del Mar Medical Research Institute) published in the journal Nature Communications has revealed that the intensity or efficiency of the activation of a protein called Notch, which is involved in the different phases of embryonic development, determines the fate of cells, i.e. if cells will form the aorta artery or blood (hematopoietic) stem cells. For artery cells, many Notch molecules need to be activated, whereas for hematopoietic cells many fewer are needed. According to Dr. Anna Bigas, the coordinator of the group on stem cells and cancer at IMIM “to reach these levels of activation, we have proven that there is a competition between two proteins that activate the Notch molecule, i.e. between two ligands, in a way that one limits the activation generated by the other to form hematopoietic stem cells”. Until now it was known, thanks to the studies conducted by this same group and others, that the Notch activation was essential to form arteries and hematopoietic stem cells. It was also known that the proteins responsible for this activation were ligands Delta4 and Jagged1, respectively. With this study, researchers have shown how this signal works to reach a certain level of activation and form the two different types of cells.
Més informació "A step forward in obtaining blood stem cells in laboratory"
21/09/2015 - Press release
An uncommon variant of the gene EN1 contributes to bone mineral density and osteoporotic fractures, according to a study recently published in the journal Nature. Daniel Grinberg, expert in the Department of Genetics of the University of Barcelona (UB) and member of the Institute of Biomedicine of the UB (IBUB), has participated in the study. Xavier Nogués and Natàlia Garcia Giralt, experts at the Service of Internal Medicine of the Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) also participate in the study, which is led by Brent Richards, professor at McGill University (Montreal, Canada). The study is also part of a research line on bone pathologies developed by the Centre for Biomedical Network Research on Rare Diseases (CIBERER), led by professors Daniel Grinberg and Susana Balcells (Department of Genetics of the UB and IBUB) with the collaboration of experts on internal medicine from the Hospital del Mar and the IMIM.
07/09/2015 - Press release
The CARDIoGRAMplusC4D Consortium, an international project in which researchers from theIMIM (Hospital del Mar Medial Research Institute) participated as the only Spanish participants, has identified 58 DNA loci or regions, 10 of which are new, linked to the risk of experiencing an ischemic heart disease. These 58 loci, besides confirming the relevance of controlling cholesterol levels and inflammation, identify in a novel way the relevance of the functioning of the arterial wall in the origin of this disease. The study is published in the prestigious journal Nature Genetics and is the first to have systematically analysed 2.7 million rare genetic characteristics. Ischemic heart disease is the leading cause of death in industrialised countries and can appear as an angina pectoris, a myocardial infarction and, sometimes, as sudden death. It is known that genetic factors account for 40 to 50% of the risk of suffering the disease, and this explains why great efforts are being invested to identify the genetic characteristics associated to this pathology, after 48 genetic characteristics have been identified in previous studies, some of which by this same research group.
Més informació "New clues on the genetic basis of myocardial infarction"
18/05/2015 - Press release
Under Horizon 2020, the EU has funded the 3.5 million project MedBioinformatics. This project aims to develop useful bioinformatics tools and applications, and autonomously usable for analysing the huge amount of data and knowledge generated in healthcare and biomedical research in order to facilitate translational research and precision medicine.The Hospital del Mar Medical Research Institute of Barcelona (IMIM) coordinates the EU-funded MedBioinformatics research project. According to Prof. Ferran Sanz, director of the IMIM-UPF Research Programme on Biomedical Informatics (GRIB) and coordinator of this project, "most potential users, i.e. translational researchers and health professionals, do not have adequate tools to efficiently exploit this large and heterogeneous amount of information. So far, efforts to develop bioinformatics methods and tools have not produced the expected impact in healthcare environments"
13/05/2015 - Press release
Researchers from the Hospital del Mar Medical Research Institute (IMIM) have discovered the key role of an enzyme in the differentiation ability of embryonic stem cells. According to the study published in the journal Molecular Cell, enzyme LOXL2 would be involved in maintaining the balance between the pluripotency and the differentiation in this type of cells that can turn into any cell in the body. The study was coordinated by the researcher from the Cancer Research Programme Sandra Peiró, and explores in greater depth the knowledge on the specialization mechanism of embryonic stem cells, opening the door to a better manipulation. Researchers from the Experimental and Health Sciences Department at the Universitat Pompeu Fabra also participated in the study.
Més informació "Key role of enzyme in the pluripotency of embryonic stem cells discovered"
28/04/2015 - Press release
Chemotargets, a spin-off company of IMIM, has launched CTlink[GUI] - a commercial version of the CTlink software that offers users intuitive, interactive graphical tools enabling them to more easily analyse results obtained using this software. CTlink can be installed on any Linux, Windows or Mac computer, desktop or laptop, and can predict how a small molecule will interact with thousands of different proteins. It is designed as a computational framework for linking different systemic entities - that is, for linking molecules, proteins, pathways, side effects, organs and diseases. It is a very important tool used by biotechnology and pharmaceutical companies.
Més informació "Chemotargets launches easier-to-use, more intuitive graphical interface CTlink[GUI]"
21/04/2015 - Press release
Researchers at the Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, investigator of IMIM's research group into stem cells and cancer, have shown that inhibition of endosomal activity is a potential therapeutic strategy for the treatment of cancers with the BRAF mutated gene. This discovery is an important step in the personalisation of the treatment of colorectal cancer, as the presence of this mutation is associated with an increased resistance compared to standard therapies. Researchers from IDIBELL - the Catalan Institute of Oncology - and the Hospital de Bellvitge also participated.
19/02/2015 - Press release
Researchers at IMIM (Hospital del Mar Medical Research Institute) have applied a new computational methodology to anticipate the degree of selectivity of the molecules that are used to study protein functions and reduce the risk of establishing erroneous relations between proteins and diseases. The proteins under study could be future candidates for new therapeutic targets. The study is published in the prestigious journal ACS Chemical Biology and was selected for the cover. Molecules are essential tools for exploring protein functions, as they have the capacity to activate, inhibit and modulate their function. For many years, in order to explore protein functions, namely to know their biological role, small molecules known as 'chemical probes' have been used, which interact with the protein under study, to become a possible candidate as a new therapeutic target. However, in order for them to be truly useful, these molecules must selectively interact with the protein under study. ‘Until now, it was assumed that these chemical probes only and exclusively interacted with the protein that was being studied, so that any variations in the results of experiments were interpreted as the consequence of the selective interaction of the chemical probe with the protein under study’ comments Jordi Mestres, coordinator of the Research Group in Systems Pharmacology at the Research Programme on Biomedical Informatics (GRIB per its Spanish acronym) at IMIM and the UPF.
Més informació "The promiscuity of chemical probes discovered"
2/12/2014 - Press release
With the goal of promoting the safety of patients and the quality of healthcare in Europe, the European Commission, sponsored by the Italian Presidency, has organised a meeting in Rome on 2nd and 3rd December with the participation of healthcare experts, researchers, politicians and international journalists, to discuss, from different perspectives, how to promote the quality of medical healthcare through healthcare systems and how to improve security in hospitals. IMIM’s project is the only one selected from Spain. The meeting will focus on communicating the results of some projects funded through the EU Healthcare Programme and the impact on the daily lives of Europeans. From all projects submitted, only 8 have been selected in several areas, one of them being the EURHOBOP Project (EURopean Hospital Benchmarking by Outcomes in acute coronary syndrome Processes), coordinated by Dr. Jaume Marrugat, a researcher from the research group on cardiovascular epidemiology and genetics at IMIM (Hospital del Mar Medical Research Institute).
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
